By Sara So, L.C.P.C.
Psychedelic experiences are known for being exceptionally intense and unpredictable, placing patients in states of heightened vulnerability. For individuals carrying a history of trauma, navigating this profound emotional and psychological exposure requires a deeply thoughtful, specialized approach to clinical care. This is where the principles of trauma-informed care (TIC) become essential to modern psychiatric practice.
Trauma-informed care is rooted in the fundamental recognition that traumatic experiences can exert enduring, profound effects on an individual’s emotional well-being, interpersonal relationships, bodily awareness, and core sense of safety. Rather than viewing trauma as an isolated event, a trauma-informed framework encourages healthcare providers to actively construct clinical conditions that promote physical and psychological safety, personal choice, mutual trust, and a restored sense of control, while simultaneously mitigating the inherent risks of re-traumatization.
These guiding principles are increasingly recognized as vital components in the burgeoning field of psychedelic-assisted therapy. As clinical research expands and public interest grows, the intersection of trauma care and altered states of consciousness demands rigorous attention from practitioners across the mental health landscape.
What Is Psychedelic-Assisted Therapy?
Psychedelic-assisted therapy, commonly referred to as PAT, represents a specialized clinical model that combines the administration of a psychedelic substance with comprehensive psychological support and psychotherapy. Depending on the specific treatment protocols, clinical trials, or research frameworks involved, clinicians may utilize a variety of established psychotherapeutic modalities, including Acceptance and Commitment Therapy (ACT), Cognitive Behavioral Therapy (CBT), or other intensive forms of talk therapy to help patients process their experiences.
PAT generally encompasses three distinct structural stages: thorough preparation before the dosing session, supportive care during the acute pharmacological experience, and structured integration afterward. Throughout this entire continuum, a patient’s internal psychological mindset—widely referred to as "set"—and the external physical and interpersonal environment, known as "setting," play critical roles in shaping the therapeutic outcome.
The regulatory landscape surrounding these substances adds a layer of complexity to clinical delivery. In the United States, the vast majority of classic psychedelics remain classified as Schedule I controlled substances at the federal level, with ketamine serving as a notable legal exception for off-label or specialized clinical use. Consequently, much of the research and treatment involving substances such as psilocybin and MDMA must take place strictly within the confines of clinical trials or other legally authorized, highly regulated settings. Because clinical trials are inherently standardized and time-limited, practitioners often face unique challenges when attempting to deeply tailor care to the distinct, individualized needs of a patient carrying complex psychological wounds.
How Trauma Can Surface During Psychedelic Therapy
Trauma can manifest in a multitude of ways, originating either from a single, isolated overwhelming event or from chronic, repeated experiences over time. Complex trauma, in particular, generally involves prolonged or repetitive traumatic experiences, frequently occurring within crucial interpersonal dynamics, such as those involving primary caregivers, trusted figures, or authority figures.
When individuals with such histories enter psychedelic therapy, these deep-seated experiences can emerge during any stage of the process, much like they can surface during traditional, non-psychedelic psychotherapy. However, psychedelics introduce an additional, powerful layer to the therapeutic equation. These substances have the capacity to dramatically intensify emotions, unearth buried memories, magnify bodily sensations, and alter standard perceptions, all while fundamentally shifting a person’s usual sense of internal control and psychological defense mechanisms.
Under the influence of these compounds, a patient may encounter overwhelming fear, profound disorientation, intense feelings of helplessness, or distressing memories with unusual vividness and emotional force. This is precisely why trauma-informed care is so critical; it equips therapists and clinical teams to proactively anticipate and prepare for these complex emotional possibilities rather than merely reacting after acute distress has already manifested in the treatment room.
What Does Trauma-Informed Psychedelic Care Look Like?
Trauma-informed psychedelic care is not merely an isolated intervention; it is a comprehensive approach that actively shapes and informs the entire therapeutic relationship and process. At its core, this framework is dedicated to fiercely protecting patient agency, maintaining steadfast relational safety, respecting firm personal boundaries, and treating informed consent as a continuous, dynamic dialogue rather than a one-time signature on a form.
Before a patient ever steps foot into a dosing session, the therapist and patient engage in collaborative discussions. They might explore specific grounding techniques that the patient has found helpful in the past, as well as identify specific words, physical behaviors, or interpersonal interactions that could inadvertently increase distress. Initiating these conversations early allows the patient to retain a meaningful, active voice in the direction of their care before they enter an altered state of consciousness where verbal communication may become significantly more challenging.
Preparation: Building Safety and Trust
The preparation phase holds exceptional importance for individuals with histories of complex trauma, as their previous life experiences may have severely disrupted their capacity to build trust, navigate interpersonal relationships, and feel fundamentally secure in their environment.
Trauma-informed preparation often involves scheduling additional preparatory sessions to allow ample time for rapport-building. During this time, clinicians and patients practice specific grounding techniques together, discuss how trauma symptoms typically manifest on both emotional and physiological levels, and collaboratively formulate a concrete plan for managing distress should it arise during the dosing experience. In instances where significant, unresolved safety concerns or acute instability arise during preparation, the clinical team may determine that delaying or canceling the dosing session is the most responsible course of action to protect the patient’s well-being.
Planning for Supportive Touch
Because psychedelic experiences can leave patients in states of unusual vulnerability, the question of physical contact during therapy requires meticulous forethought. If supportive touch is being considered as a potential grounding technique to help anchor a patient during moments of intense emotional release, it must be discussed thoroughly beforehand.
Potential examples of supportive touch might include gentle hand-holding or placing a reassuring hand on the patient’s wrist, arm, shoulder, or upper back. Crucially, consent in these scenarios must remain specific, ongoing, and entirely voluntary.
Furthermore, therapists and patients can plan for alternative methods of connection. A patient who decides they do not want direct physical touch might instead prefer to hold one end of a weighted therapeutic cushion while the therapist holds the opposite end. This creates a tangible sense of safety and interpersonal connection without requiring direct physical contact. Mapping out these possibilities in advance grants patients a higher degree of agency during a time when effectively communicating complex needs may become exceptionally difficult.
Dosing: Maintaining Consent and Safety
During the actual dosing session, the therapist’s primary responsibility is to actively nurture the relational safety and structural plans established during the preparation phase. Because psychedelics frequently produce profound disorientation, heightened vulnerability, and a temporarily reduced capacity for complex decision-making, practitioners must remain hyper-attentive to both verbal communication and subtle nonverbal cues.
For instance, if supportive touch is actively being utilized and a patient suddenly tenses their muscles, becomes completely still, alters their breathing pattern, physically pulls away, or abruptly stops speaking, the therapist must recognize these shifts as critical indicators that something within the internal experience has changed. Previously given consent should never be treated as permanent, irrevocable permission. In such moments, the therapist can immediately pause, physically create safe space, and verbally communicate what actions they are taking to reassure the patient.
Maintaining clear boundaries, well-defined professional roles, ongoing consent checks, and careful, unwavering attention to the patient’s moment-to-moment responses are essential practices that safeguard both physical and emotional safety throughout the acute experience.
Integration: Supporting What Happens Afterward
Importantly, the framework of trauma-informed care does not conclude when the acute effects of the psychedelic substance begin to wane. Difficult emotions, cognitive shifts, or delayed trauma-related symptoms frequently emerge hours, days, or even weeks after the dosing session has ended.
During the critical integration phase, the therapist works collaboratively with the patient to help them make sense of, contextualize, and respond constructively to the material that surfaced during the experience. This supportive work may incorporate previously identified coping strategies, such as structured breathing exercises, physical grounding practices, familiar daily routines, and engagement with trusted social support networks. Should significant trauma-related symptoms or destabilization emerge, scheduling additional integration sessions or connecting the patient with specialized, trauma-informed mental health treatment may be necessary and appropriate.
Ideally, these vital resources and aftercare pathways are identified proactively during the preparation phase, ensuring that patients already know precisely where they can turn if they require additional support once they leave the clinical setting.
A Framework for Safer Psychedelic Care
Ultimately, trauma-informed care transcends being merely a strategic tool for managing a difficult or challenging psychedelic journey. Instead, it serves as a comprehensive overarching framework for designing and delivering clinical care across the entire continuum of treatment.
This model challenges therapists, guides, and broader clinical care teams to consistently prioritize safety, trust, consent, personal choice, boundaries, power dynamics, and individual needs at every single stage of the process—from initial preparation through the acute dosing session, integration, and long-term aftercare.
Because psychedelic experiences can place individuals in uniquely vulnerable psychological states, developing a deep, nuanced understanding of how trauma interacts with these powerful compounds is clinically essential. By thoughtfully incorporating trauma-informed principles into every facet of psychedelic-assisted therapy, the mental health field can work toward creating safer, more compassionate therapeutic environments while empowering patients to maintain a steadfast sense of agency in their own healing journeys.
Sara So, L.C.P.C., is a psychotherapist with more than a decade of experience in academic research. They hold a Master of Health Science from Johns Hopkins University, a Master of Science from Loyola University Maryland, and a Bachelor of Arts from Pennsylvania State University. Prior to joining Sunstone Therapies, they served as a Psychiatric Therapist at the Center for Psychedelic and Consciousness Research at Johns Hopkins University.